Deramciclane (Egis).

  title={Deramciclane (Egis).},
  author={Sulev K{\~o}ks and E. E. Vasar},
  journal={Current opinion in investigational drugs},
  volume={3 2},
Egis, in collaboration with Orion Pharma and Pharmacia, is developing deramciclane, a 5-HT(2A) antagonist and a 5-HT(2C) inverse agonist, as a potential treatment for anxiety disorders [300642]. The compound was also in development for epilepsy but no recent development has been reported for this indication. As of May 2001, comprehensive phase III studies with deramciclane in ten European countries were progressing according to plan [399853], [408534]. By August 2001, phase III studies were… CONTINUE READING